Key result
SPH3127 treatment attenuated body weight loss, reduced clinical severity, alleviated colon mucosal ulceration, and prevented death in RenTg mice with experimental colitis.
Why the study?
The renin-angiotensin system plays an important role in inflammatory bowel disease pathogenesis, but few studies have directly assessed the therapeutic effect of renin inhibitors on colitis development.
Does SPH3127 (sitokiren) suppress colitis development in mouse models of experimental colitis?
Does SPH3127 (sitokiren) suppress colitis development in mouse models of experimental colitis?
SPH3127, a novel renin inhibitor, effectively blocks colitis development in mouse models by suppressing mucosal TH1 and TH17 activation and promoting IL-10 production.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for renin inhibition in IBD; human trials needed before clinical relevance can be assessed.
BACKGROUND: Emerging evidence suggests that the renin-angiotensin system plays an important role in the pathogenesis of inflammatory bowel disease, but few studies have directly assessed the therapeutic effect of renin inhibitors on colitis development. METHOD: Experimental colitis was induced in wild-type C57BL/6 mice and renin transgenic (RenTg) mice by 2,4,6-trinitrobenzene sulfonic acid (TNBS). Following intrarectal TNBS instillation, the mice were treated with SPH3127 (sitokiren), a small-molecule renin inhibitor, twice a day by intraperitoneal injection or oral gavage. The therapeutic effect of SPH3127 was evaluated by assessing clinical symptoms, histological injuries, and colonic mucosal inflammatory parameters in these mice. RESULTS: SPH3127 treatment by either delivery route markedly attenuated body weight loss, reduced clinical severity, alleviated colon mucosal ulceration in both C57BL/6 and RenTg mice, and prevented animal death in the case of RenTg mice. SPH3127 treatment blocked the local induction of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IFN-γ, IL-17) and promoted the production of anti-inflammatory cytokine IL-10 in the colon. Fluorescence-activated cell sorting analysis revealed that SPH3127 substantially diminished the accumulation of TH1 and TH17 cells in the colonic mucosa and confirmed that SPH3127-induced IL-10 production from mucosal CD25+ T cells in the mice. CONCLUSIONS: These results demonstrate that SPH3127 is able to effectively block colitis development in mouse experimental colitis models. Its anti-colitogenic activity is achieved at least in part by suppressing mucosal TH1 and TH17 activation while promoting IL-10 production from mucosal CD25+ T cells, thus forming an anti-inflammatory environment in the colonic mucosa.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied Experimental colitis. SPH3127 (sitokiren) was evaluated on Clinical symptoms, histological injuries, and colonic mucosal inflammatory parameters. SPH3127 treatment attenuated body weight loss, reduced clinical severity, alleviated colon mucosal ulceration, and prevented death in RenTg mice with experimental colitis.
Synapse has enriched 10 related papers. Consider them for comparative context: